Skip to main content

News

DEXA Still Needed While on Bisphosphonates

Reuters reports that a study of 6629 Canadian women with osteoporosis taking bisphosphonates found that nearly one in five had a decrease in bone density while on medication. (Citation source: http://buff.ly/2afb7nj) 

Prevalence of Spondyloarthropathy in Fibromyalgia

With the introduction of ASAS criteria for the diagnosis of axial and peripheral spondyloarthropathy, there has been a debate about whether patients with fibromyalgia (FM) could be mistaken for a spondyloarthropathy, or vice versa.

SAPHO Syndrome Revisted

SAPHO is an acronym that describes a constellation of findings (synovitis, acne, pustulosis, hyperostosis, and osteitis) that defines this rare syndrome. 

Will Patent Extensions Delay Biosimilar Arrivals?

In the last 6 months, the FDA Arthritis Advisory Committee has recommended three biosimilars (CT-P13, GP-2015, ABP-501) for approval, with one achieving FDA approval Inflectra/CT-P13) and the other two pending a probable approval in the months to come.

ORBIT Study Shows Rituximab is Non-Inferior to TNF Inhibitors in Biologic Naive Patients

Porter and colleagues have reported that both rituximab (RTX) and tumour necrosis factor inhibitors (TNFi)  are equally and highly effective in early, active, biologic-naive rheumatoid arthritis patients.

Increaed GI Perforations with Tocilizumab Seen in German Registry Analysis

The issue of lower intestinal tract perforation (LIP) is no novelty to rheumatologists since the RA treatment paradigm shifted from use of NSAIDs (the most common cause of upper GI tract perforations) to steroids and non-steroidal DMARDs.

RheumNow Week in Review – 15 July 2016

Dr. Jack Cush reviews highlights from this week's rheumatology news on RheumNow.com.

Sandoz Etanercept Biosimilar Voted for Approval by FDA Arthritis Advisory Committee

The Food and Drug Administration’s Arthritis Advisory Committee (AAC) yesterday recommended that the Sandoz etanercept (Enbrel) biosimilar (GP-2015) be approved for use in the United States.

FDA Approves Xiidra (Lifitegrast) for Dry Eyes

MedScape has reported that the US Food and Drug Administration (FDA) has approved lifitegrast ophthalmic solution (Xiidra, Shire) for the treatment of signs and symptoms of dry eye disease.

Gut Microbiome Shapes Risk and Response in Rheumatoid Arthritis

In Genome Medicine, Mayo Clinic researchers investigated a cohort of rheumatoid arthritis (RA) patients, their relatives and a healthy control group analyzing the gut microbiome vial16S ribosomal DNA analysis of fecal samples.

FDA Arthritis Advisory Committee Recommends Approval of Adalimumab Biosimilar

The Food and Drug Administration’s Arthritis Advisory Committee yesterday recommended that Amgen biosimilar (ABP 501) to Humira (adalimumab) be approved for use in the United States.  

FDA Says Cryotherapy Lacks Evidence, Poses Risks

Cryotherapy is a non-FDA approved treatment that has been promoted to treat post-athletic injury, osteoarthritis,rheumatoid arthritis, fibromyalgia, alzheimers, migraines, asthma, multiple sclerosis, etc. Cryotherapy may be as simple as ice packs on a localized portion of the body, such as the lower back, or may involve whole body cryotherapy.

Academic Female Physicians Paid Less than Male Counterparts

Female academic physicians at public medical schools had lower average salaries than their male counterparts, a disparity that was only partly accounted for by age, experience, medical specialty, faculty rank and other factors, according to an article published online by JAMA Internal Medicine.

EULAR Revised Recommendations for Fibromyalgia

The European League Against Rheumatism (EULAR) has published updated recommendations on the management of fibromyalgia in the Annals of the Rheumatic Diseases (Citation source http://buff.ly/29I7e8C). 

Vagal Stimulation Improves Cytokine Production and Rheumatoid Disease Activity

PNAS has published a study wherein an inducible “inflammatory reflex” delivered by vagus nerve stimulation was shown to inhibit the production of tumor necrosis factor (TNF), an inflammatory molecule that is a major therapeutic target in an animal model of rheumatoid arthritis (RA).

×